Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of IPX159 in the Treatment of Moderate to Severe Restless Legs Syndrome (RLS)

NCT01521663 is registered in ClinicalTrials.gov with Impax Laboratories, LLC as lead sponsor.

NCT NCT01521663
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01521663 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of IPX159 in the Treatment of Moderate to Severe Restless Legs Syndrome (RLS)
Lead sponsor
Impax Laboratories, LLC
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2011
Completion date
February 28, 2013
Enrollment
159 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

restless legs syndrome